Acer Therapeutics (ACER) Stock Price, News & Analysis

Company Overview

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The company's pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-801 for the treatment of induced Vasomotor Symptoms, post-traumatic stress disorder, and prostate cancer; and OLPRUVA, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease. It has a license agreement with Sanofi to acquire worldwide rights to Osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist; an option agreement with Relief for the development, regulatory approval, and commercialization of OLPRUVA; and an agreement with Emory University to acquire the worldwide intellectual property rights to a family of patents and patent applications related to the use of neurokinin receptor antagonists in managing conditioned fear and treating anxiety disorders, including post-traumatic stress disorder. The company was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Key Stats

• Today's Range: $0.66 to $0.85
• 50-Day Range: $0.66 to $0.90
• 52-Week Range: $0.55 to $4.56
• Volume: 574,675 shs
• Average Volume: N/A
• Market Capitalization: $16.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ACER Stock Analysis - Frequently Asked Questions

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc. (NASDAQ:ACER) posted its quarterly earnings results on Friday, November, 19th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.05.

Does Acer Therapeutics have any subsidiaries?

The following companies are subsidiaries of Acer Therapeutics: Opexa Therapeutics Inc..

What other stocks do shareholders of Acer Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Acer Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), CymaBay Therapeutics (CBAY), GE Aerospace (GE), Meta Platforms (META), Adobe (ADBE) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 11/19/2021
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ACER
• CIK: 1069308
• Web: www.acertx.com
• Phone: (844) 902-6100
• Fax: 281-872-8585
• Employees: 30
• Year Founded: 2013

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 24,460,000
• Free Float: 19,522,000
• Market Cap: $16.15 million
• Optionable: Not Optionable
• Beta: N/A